GGHC
NKTR icon

Gilder Gagnon Howe & Co’s Nektar Therapeutics NKTR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.6M Buy
271,758
+63,456
+30% +$3.61M 0.23% 88
2025
Q4 		$8.81M Sell
208,302
-16,526
-7% -$925K 0.09% 121
2025
Q3 		$12.8M Buy
224,828
+195,926
+678% +$6.49M 0.13% 109
2025
Q2 		$747K Buy
28,902
+1,410
+5% +$15.8K 0.01% 209
2025
Q1 		$280K Buy
+27,492
New +$359K ﹤0.01% 224

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Gilder Gagnon Howe & Co's NKTR Position: Q1 2026 in Review

Gilder Gagnon Howe & Co increased its Nektar Therapeutics (NKTR) stake by 30% in Q1 2026, buying an estimated $3.61M and bringing the position to 271,758 shares worth $19.6M. The position accounts for 0.23% of the portfolio, ranked #88.

Gilder Gagnon Howe & Co first reported a position in NKTR in Q1 2025 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Gilder Gagnon Howe & Co held 271,758 shares of Nektar Therapeutics worth $19.6M as of Q1 2026.
  • Gilder Gagnon Howe & Co bought 63,456 Nektar Therapeutics shares in Q1 2026, an estimated $3.61M.
  • Nektar Therapeutics made up 0.23% of Gilder Gagnon Howe & Co's portfolio in Q1 2026, its #88 holding.
  • Gilder Gagnon Howe & Co first reported a position in Nektar Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.